about
Use of an in vivo FTA assay to assess the magnitude, functional avidity and epitope variant cross-reactivity of T cell responses following HIV-1 recombinant poxvirus vaccinationContraception in mice immunized with recombinant zona pellucida subunit 3 proteins correlates with Th2 responses and the levels of interleukin 4 expressed by CD4+ cellsExpression of mouse interleukin-4 by a recombinant ectromelia virus suppresses cytolytic lymphocyte responses and overcomes genetic resistance to mousepox.Reduced interleukin-4 receptor α expression on CD8+ T cells correlates with higher quality anti-viral immunity.IL-17A expression in HIV-specific CD8 T cells is regulated by IL-4/IL-13 following HIV-1 prime-boost immunization.Role of novel type I interferon epsilon in viral infection and mucosal immunity.Human immunodeficiency virus-1 vaccine design: where do we go now?IL-4 and IL-13 receptors: Roles in immunity and powerful vaccine adjuvants.Myxoma virus encodes an alpha2,3-sialyltransferase that enhances virulence.Identification of biomarkers to measure HIV-specific mucosal and systemic CD8(+) T-cell immunity using single cell Fluidigm 48.48 Dynamic arrays.Recombinant fowlpox virus vector-based vaccines: expression kinetics, dissemination and safety profile following intranasal delivery.Construction of recombinant myxoma viruses expressing foreign genes from different intergenic sites without associated attenuation.Progress towards using recombinant myxoma virus as a vector for fertility control in rabbits.Contraceptive responses of mice immunized with purified recombinant mouse zona pellucida subunit 3 (mZP3) proteins.Different HIV pox viral vector-based vaccines and adjuvants can induce unique antigen presenting cells that modulate CD8 T cell avidity.Novel HIV IL-4R antagonist vaccine strategy can induce both high avidity CD8 T and B cell immunity with greater protective efficacy.Progresses in DNA-based heterologous prime-boost immunization strategies.IL-4 and IL-13 mediated down-regulation of CD8 expression levels can dampen anti-viral CD8⁺ T cell avidity following HIV-1 recombinant pox viral vaccination.Infertility in mice induced by a recombinant ectromelia virus expressing mouse zona pellucida glycoprotein 3.IL-12p40 and IL-18 play pivotal roles in orchestrating the cell-mediated immune response to a poxvirus infection.Immunocontraceptive effects on female rabbits infected with recombinant myxoma virus expressing rabbit ZP2 or ZP3.Infertility in female rabbits (Oryctolagus cuniculus) alloimmunized with the rabbit zona pellucida protein ZPB either as a purified recombinant protein or expressed by recombinant myxoma virus.Unique IL-13Rα2-based HIV-1 vaccine strategy to enhance mucosal immunity, CD8(+) T-cell avidity and protective immunity.Role of novel type I interferon epsilon in mucosal immunity.Vaccination route can significantly alter the innate lymphoid cell subsets: a feedback between IL-13 and IFN-γ.Modulation of expression of the hepatitis B virus surface antigen gene by the viral X-gene productCloning and analysis of pif, replication and leading regions of the F plasmidA novel viral alpha2,3-sialyltransferase (v-ST3Gal I): transfer of sialic acid to fucosylated acceptors
P50
Q27314609-32425E1B-25D9-45DB-A328-B35B41005F5CQ28510273-0D63A93A-1684-4B35-881C-0E74F739FE97Q33836059-F89353F9-35E6-4776-990C-0EA3F8C2AC0AQ34576972-F277E557-7F80-41E0-83A7-80F789DCDA04Q35149947-2C988D31-6040-4EF7-8EEC-AC4C6DEB6E4BQ36346860-54C66750-750C-410D-BECC-C34C4B82FBD5Q37801269-DBD6EB29-2FD0-424E-B1B5-7A9BACF06D44Q38243513-5FC022E1-65FD-4695-80A3-AF4BEE00B818Q38328475-C37B6360-EEBC-48B1-B35B-4CB7D0449C3DQ40372613-4A7BA6C0-DA10-4C93-9E83-3B4C2BD8DCF9Q40384316-37299077-9BF7-456D-BC97-96A1F1741D1EQ41188635-C5981FD9-711F-42ED-AF8B-92CDDCA5DED3Q41435850-FA29DD2A-D5A3-4B21-8D60-A5812A31FE13Q42047523-F1517A33-AFF3-402D-AAEE-8EA91CCAD31DQ42185673-C3007DA7-9645-4745-BADC-95C1CDB157B2Q42198317-75E88C4E-0090-4BE8-BB9D-D79952424E94Q42225981-C6027323-B640-481D-A96F-EA1C23833E52Q42277634-BF7B0768-AE61-4095-919D-20EDB0771998Q43522569-0367D5AD-90AA-446B-9F71-396F0EB17169Q44583893-49AB3225-EF36-4A92-80A9-81315568942FQ45422252-30624B85-F32D-4E4E-AB14-235407F6EB94Q45747688-12328135-2D26-4304-9511-DA2243EE11F3Q46391524-2AF18E8A-FCDB-4232-A2D5-355FA0BBC4ABQ46988037-DD969DFF-AF2C-48E3-B9F2-9D3074A3EEDBQ54105139-98BD6B97-F405-4401-B540-5E4FD0390AC3Q57634199-89DA4512-44FD-4B1C-9EC4-D4C2C5FA811FQ72406873-71C4593D-E9F7-4F15-808F-4AE4D1F747A0Q73514938-9A18A67A-6E85-4D1D-9E16-974015314DB7
P50
description
onderzoeker
@nl
researcher ORCID ID = 0000-0002-6550-6251
@en
name
Ronald J Jackson
@ast
Ronald J Jackson
@en
Ronald J Jackson
@nl
type
label
Ronald J Jackson
@ast
Ronald J Jackson
@en
Ronald J Jackson
@nl
prefLabel
Ronald J Jackson
@ast
Ronald J Jackson
@en
Ronald J Jackson
@nl
P106
P31
P496
0000-0002-6550-6251